GLP-1 Story Continues Here are the key figures since Q2 2024: Q2 2024: GLP-1 revenue: $12 million Total revenue: $325 million Share of GLP-1 revenue: 4 % Q3 2024: GLP-1 revenue: $55 million* Total revenue: $441 million Share of GLP-1 revenue: 12 % Q4 2024: GLP-1 revenue: $162 million* Total revenue: $488 million Share of GLP-1 revenue: 33 % Q1 2025: GLP-1 revenue: $ 230 million Total revenue: $596 million Share of GLP-1 revenue: 39 % Q2 2025: GLP-1 revenue: $190 million Total revenue: $545 million Share of GLP-1 revenue: 35 % * Estimate based on the $229M GLP-1 revenue for FY 2024 Revenue Momentum Stalls Amid GLP-1 Reliance Historically Hims has issued conservative guidance and then surpassed the top end of its range
Kickstart Your Longevity and Weight Loss With Lipotropic Injections from Ivy Rx Ivy Rxs at-home MIC/B12 injection program delivers pharmaceutical-grade ingredients, expert support, and all necessary supplies for a transparent monthly price starting at $179
This is a genuine lifeline for uninsured patients who couldn't otherwise afford treatment, though it requires annual reapplication
The authors highlight BPC-157, writing its clinical validation in human subjects is virtually non-existent, and GHK-Cu, stating that injecting it could expose joint tissues to excess copper, impairing cell function
Soft lithography in biology and microbiology